Is Q32 Bio Inc (NASDAQ: QTTB) Proving The Doubters Wrong?

Q32 Bio Inc (QTTB) concluded trading on Thursday at a closing price of $3.32, with 59.6 million shares of worth about $197.87 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -9.29% during that period and on July 10, 2025 the price saw a gain of about 119.87%. Currently the company’s common shares owned by public are about 12.20M shares, out of which, 4.44M shares are available for trading.

Stock saw a price change of 130.56% in past 5 days and over the past one month there was a price change of 82.42%. Year-to-date (YTD), QTTB shares are showing a performance of -82.53% which decreased to -3.49% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.35 but also hit the highest price of $53.79 during that period. The average intraday trading volume for Q32 Bio Inc shares is 1.12 million. The stock is currently trading 103.77% above its 20-day simple moving average (SMA20), while that difference is up 98.21% for SMA50 and it goes to -74.63% lower than SMA200.

Q32 Bio Inc (NASDAQ: QTTB) currently have 12.20M outstanding shares and institutions hold larger chunk of about 19.06% of that.

The stock has a current market capitalization of $40.50M and its 3Y-monthly beta is at -0.03. It has posted earnings per share of -$4.95 in the same period. It has Quick Ratio of 4.71. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for QTTB, volatility over the week remained 33.64% while standing at 13.63% over the month.

Stock’s fiscal year EPS is expected to rise by 47.27% while it is estimated to decrease by -27.66% in next year. EPS is likely to shrink at an annualized rate of 4.80% for next 5-years, compared to annual growth of 31.75% made by the stock over the past 5-years.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on February 11, 2025 offering a Neutral rating for the stock and assigned a target price range of between $20 and $4 to it. Coverage by BMO Capital Markets stated Q32 Bio Inc (QTTB) stock as a Market perform in their note to investors on February 11, 2025, suggesting a price target of $3 for the stock. On December 11, 2024, Wells Fargo Downgrade their recommendations, while on December 11, 2024, Raymond James Downgrade their ratings for the stock with a price target of $22. Stock get a Market perform rating from Leerink Partners on December 11, 2024.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.